Syndax Q2 Revenue Jumps 92% to $73M, Loss Narrows; Pipeline Catalysts Loom
SNDX sits 86% above its 52-week low of $9.68.
Summary
Syndax reported Q2 2026 revenue of $72.8M, a 92% increase, with both Revuforj and Niktimvo delivering strong growth. The net loss narrowed to $49.4M, and full-year expense guidance of $400M was reiterated. Several pipeline milestones are expected in the coming quarters.
Key Events · Earnings and Guidance · SNDX
-
Revenue Surges 92% to $72.8M
Total Q2 revenue hit $72.8M, powered by Revuforj net revenue of $54.7M (+91% YoY) and Niktimvo collaboration revenue of $18.1M (+93% YoY). Both products are annualizing above $200M.
-
Net Loss Narrows to $49.4M
The net loss improved to $49.4M ($0.55/share) from $71.8M ($0.83/share) a year ago, reflecting revenue growth and controlled operating expenses.
-
Cash Position of $575M; Path to Profitability
Cash and investments stood at $575.1M as of June 30, 2026. Management expects current cash plus anticipated revenues to fund operations to profitability.
-
Full-Year Expense Guidance Reiterated
For 2026, R&D plus SG&A expenses are expected to be approximately $400M, excluding $50M in non-cash stock compensation.
Analysis · SNDX · Life Sciences
A strong quarter puts both commercial drugs on an annual run rate above $200M each. Revuforj net revenue climbed 91% year-over-year to $54.7M, fueled by longer treatment durations and an expanding prescriber base, while Niktimvo collaboration revenue reached $18.1M on robust demand. The net loss narrowed to $49.4M from $71.8M a year ago. With $575M in cash and a clear line of sight to profitability, the company is well-funded to advance a pipeline that includes near-term Phase 2 readouts in IPF and frontline cGVHD during Q4 2026, plus two new assets targeting NSCLC and myelofibrosis. Accelerating revenue, disciplined spending, and multiple catalysts make this a pivotal update.
At the time of this filing, SNDX was trading at $17.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.68 to $25.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.